ARCHIMED completes purchase of Standard BioTools microfluidics unit, renames it Biomark Scientific
The healthcare investment firm's acquisition of the business closed November 3, 2026, with the unit now operating independently under the Biomark Scientific name.
ARCHIMED and Standard BioTools Inc. (NASDAQ: LAB) announced on November 3, 2026 that ARCHIMED had completed its previously announced acquisition of Standard BioTools' Microfluidics Business.1 As part of ARCHIMED, the business begins operating as a standalone entity under the name Biomark Scientific.1
The unit's flagship technology centers on the Biomark platform. Biomark Scientific specializes in high-throughput and multi-assay genomics systems and will offer genomic profiling on its Biomark platform.1 Its next-generation Biomark X9 system is described as the only automated PCR, qPCR and NGS library prep system on the market, performing simultaneous profiling of multiple genomic assay readouts in a single run using patented integrated fluidic circuits.1 The platform has a long history in the sector: Biomark was previously part of Fluidigm, which was founded in 1999 and renamed Standard BioTools in 2022.1
Standard BioTools disclosed the closing in a Form 8-K filed under Item 7.01, stating that on November 3, 2026, Standard BioTools issued a joint press release with ARCHIMED announcing the closing of its previously announced sale of its Microfluidics business to ARCHIMED.1
The filing also notes other pending matters involving Standard BioTools. The communication may be deemed solicitation material related to proposed transactions involving Standard BioTools and Treeline Biosciences, Inc., and/or Standard BioTools' sale of its Mass Cytometry business to Element Biosystems, LLC.1 In connection with the Treeline transaction and related stockholder vote, Standard BioTools filed a registration statement on Form S-4, as amended, which was declared effective by the SEC on October 21, 2026.1 The definitive proxy statement/prospectus, dated October 21, 2026, was first mailed to stockholders of Standard BioTools on or about October 21, 2026.1
ARCHIMED is described in the filing as a firm that has offices in Europe, North America and Asia and is a leading investment firm focused exclusively on healthcare industries,1 and manages €15 billion across its various funds.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.